- Lymphoma survival is better than before, especially with early diagnosis; non-Hodgkin survival is generally lower than Hodgkin.
- A 2019 study found quality of life declined after treatment but improved for most over two years (~20% stayed reduced).
- Higher tumour-infiltrating T-cell and NK-cell counts are linked to longer survival.
- Concentrated mushroom-polysaccharide formulas are studied for maintaining NK-cell and macrophage activity.
Lymphoma survival today is better than it used to be, especially among patients diagnosed earlier, before the cancer begins to spread. The two main types of lymphoma are Hodgkin and non-Hodgkin lymphoma; different types have different treatments, so survival differs too. Non-Hodgkin lymphoma survival is generally lower than that of Hodgkin lymphoma. These figures will not tell you how long you have left — they can only help you understand the likelihood that your treatment will be successful.
Can survival be improved?
A 2019 study found that the physical and mental quality of life of lymphoma survivors declined after treatment, but for most participants it improved over the following two years. Unfortunately, for about 20% of participants the quality-of-life measures remained reduced. This is why the body must be restored after treatment — meaning exercise, food, and psychological balance. Clinical studies confirm that a higher number of immune cells (T-cells and NK cells) within the tumour is directly associated with longer patient survival.12 Concentrated mushroom-polysaccharide formulas are studied for their role in helping maintain NK-cell and macrophage activity.
Clinical studies link higher tumour-infiltrating T-cell and NK-cell counts with longer survival. Concentrated mushroom polysaccharides are studied for maintaining this activity.
Lentinan AXT by Zenius Labs™ →Survival varies by type and stage. Non-Hodgkin lymphoma survival is generally lower than Hodgkin lymphoma. Overall five-year relative survival for non-Hodgkin lymphoma is around 73%, and Hodgkin lymphoma is among the most treatable cancers. Survival figures indicate likelihood of successful treatment, not how long an individual has left.
Quality of life often declines after treatment but improves for most people over the following two years. Restoring the body — exercise, nutrition and psychological balance — matters. Clinical studies link a higher number of tumour-infiltrating immune cells (T-cells and NK cells) with longer survival.
Research associates higher tumour-infiltrating T-cell and NK-cell counts with longer survival. Concentrated mushroom-polysaccharide formulas such as Lentinan AXT by Zenius Labs™ are studied for their role in maintaining NK-cell and macrophage activity.